No­var­tis col­lab­o­rates with Max Foun­da­tion for can­cer

BioSpectrum (Asia) - - World News -

No­var­tis an­nounced a new col­lab­o­ra­tion with The Max Foun­da­tion to sup­port con­tin­ued ac­cess to treat­ment at no cost for nearly 34,000 cur­rent pa­tients with chronic myeloid leukemia (CML), gas­troin­testi­nal tu­mors (GIST) and other rare can­cers.

The two or­ga­ni­za­tions have been long-time col­lab­o­ra­tors in pro­vid­ing ac­cess to care for pa­tients in lower-in­come coun­tries through the Glivec In­ter­na­tional Pa­tient As­sis­tance Pro­gram (GIPAP), one of the most in­no­va­tive pa­tient as­sis­tance pro­grams ever im­ple­mented on a global scale.

The new col­lab­o­ra­tion, called CMLPath to Care (TM), is an evo­lu­tion from GIPAP, a part­ner­ship that pro­vided Glivec (ima­tinib) at no cost to di­ag­nosed pa­tients in lower-in­come coun­tries where there may not be ac­cess to re­im­burse­ment or fund­ing mech­a­nisms, and to those un­able to pay for the med­i­ca­tion.

Un­der the new ini­tia­tive, The Max Foun­da­tion, a global, pa­tient-fo­cused, non-gov­ern­men­tal or­ga­ni­za­tion (NGO), will as­sume from No­var­tis the re­spon­si­bil­ity for de­liv­er­ing the treat­ment to these pa­tients, in­clud­ing sup­ply chain man­age­ment. No­var­tis will pro­vide fund­ing and drug do­na­tion sup­port. The col­lab­o­ra­tive agree­ment runs through Q1 2021 with an op­tion to ex­tend. Dur­ing this time­frame, No­var­tis ex­pects to donate more than $29 mil­lion to the col­lab­o­ra­tion, along with ap­prox­i­mately 315,000,000 doses of medicine.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.